Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42*

Cellular migration is a fundamental process linked to diverse pathological states such as diabetes and its complications, atherosclerosis, inflammation, and cancer. The receptor for advanced glycation end products (RAGE) is a multiligand cell surface macromolecule which binds distinct ligands that accumulate in these settings. RAGE-ligand interaction evokes central changes in key biological properties of cells, including proliferation, generation of inflammatory mediators, and migration. Although RAGE-dependent signal transduction is critically dependent on its short cytoplasmic domain, to date the proximate mechanism by which this RAGE domain engages and stimulates cytoplasmic signaling pathways has yet to be identified. Here we show that the RAGE cytoplasmic domain interacts with Diaphanous-1 (Dia-1) both in vitro and in vivo. We employed the human RAGE cytoplasmic domain as “bait” in the yeast two-hybrid assay and identified the formin homology (FH1) domain of Dia-1 as a potential binding partner of this RAGE domain. Immunoprecipitation studies revealed that the RAGE cytoplasmic domain interacts with the FH1 domain of Dia-1. Down-regulation of Dia-1 expression by RNA interference blocks RAGE-mediated activation of Rac-1 and Cdc42 and, in parallel, RAGE ligand-stimulated cellular migration. Taken together, these findings indicate that the interaction of the RAGE cytoplasmic domain with Dia-1 is required to transduce extracellular environmental cues evoked by binding of RAGE ligands to their cell surface receptor, a chief consequence of which is Rac-1 and Cdc42 activation and cellular migration. Because RAGE and Dia-1 are implicated in the regulation of inflammatory, vascular, and transformed cell migration, these findings highlight this interaction as a novel target for therapeutic intervention in inflammation, atherosclerosis, diabetes, and cancer.

[1]  A. Ong,et al.  Activation of TRPP2 through mDia1‐dependent voltage gating , 2008, The EMBO journal.

[2]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  Shitao Li,et al.  Receptor for advanced glycation end products (RAGE) mediates neuronal differentiation and neurite outgrowth , 2008, Journal of neuroscience research.

[4]  L. Riboni,et al.  HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration , 2008, Journal of Neuro-Oncology.

[5]  R. Ramasamy,et al.  Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. , 2008, The Journal of clinical investigation.

[6]  K. Nozaki,et al.  The Rho-mDia1 Pathway Regulates Cell Polarity and Focal Adhesion Turnover in Migrating Cells through Mobilizing Apc and c-Src , 2006, Molecular and Cellular Biology.

[7]  M. Eck,et al.  Structure of the autoinhibitory switch in formin mDia1. , 2006, Structure.

[8]  A. Wittinghofer,et al.  The regulation of mDia1 by autoinhibition and its release by Rho•GTP , 2005, The EMBO journal.

[9]  H. Higgs Formin proteins: a domain-based approach. , 2005, Trends in biochemical sciences.

[10]  M. Machius,et al.  Structural basis of Rho GTPase-mediated activation of the formin mDia1. , 2005, Molecular cell.

[11]  M. Connelly,et al.  Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. , 2005, The Journal of clinical investigation.

[12]  H. Higgs,et al.  Dissecting Requirements for Auto-inhibition of Actin Nucleation by the Formin, mDia1* , 2005, Journal of Biological Chemistry.

[13]  K. Miyazono,et al.  Negative regulation of transforming growth factor-β (TGF-β) signaling by WW domain-containing protein 1 (WWP1) , 2004, Oncogene.

[14]  J. Luban,et al.  Blockade of Late Stages of Autoimmune Diabetes by Inhibition of the Receptor for Advanced Glycation End Products1 , 2004, The Journal of Immunology.

[15]  D. Sage,et al.  EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation with CD21: formin interactions with the cytoplasmic domain of human CD21 , 2004, Journal of Cell Science.

[16]  M. Tominaga,et al.  DIP (mDia interacting protein) is a key molecule regulating Rho and Rac in a Src‐dependent manner , 2004, The EMBO journal.

[17]  H. Higgs,et al.  The Mouse Formin mDia1 Is a Potent Actin Nucleation Factor Regulated by Autoinhibition , 2003, Current Biology.

[18]  A. Alberts,et al.  The formins: active scaffolds that remodel the cytoskeleton. , 2003, Trends in cell biology.

[19]  E. Topol,et al.  Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury , 2003, Circulation.

[20]  K. Nozaki,et al.  Control of axon elongation via an SDF-1α/Rho/mDia pathway in cultured cerebellar granule neurons , 2003, The Journal of cell biology.

[21]  X. Chen,et al.  Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system , 2003, Nature Medicine.

[22]  T. Tominaga,et al.  mDia-interacting Protein Acts Downstream of Rho-mDia and Modifies Src Activation and Stress Fiber Formation* , 2001, The Journal of Biological Chemistry.

[23]  A. Krebs,et al.  Characterization of functional domains of mDia1, a link between the small GTPase Rho and the actin cytoskeleton. , 2001, Journal of cell science.

[24]  M. Crow,et al.  Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. , 2001, Diabetes.

[25]  V. D’Agati,et al.  Receptor for Advanced Glycation End Products Mediates Inflammation and Enhanced Expression of Tissue Factor in Vasculature of Diabetic Apolipoprotein E–Null Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[26]  W. Hung,et al.  Role of receptor for advanced glycation end‐product (RAGE) and the JAK/STAT‐signaling pathway in AGE‐induced collagen production in NRK‐49F cells , 2001, Journal of cellular biochemistry.

[27]  A. Mammoto,et al.  Rho small G-protein-dependent binding of mDia to an Src homology 3 domain-containing IRSp53/BAIAP2. , 2000, Biochemical and biophysical research communications.

[28]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[29]  H. Huttunen,et al.  Receptor for Advanced Glycation End Products (RAGE)-mediated Neurite Outgrowth and Activation of NF-κB Require the Cytoplasmic Domain of the Receptor but Different Downstream Signaling Pathways* , 1999, The Journal of Biological Chemistry.

[30]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[31]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[32]  M. King,et al.  Nonsyndromic deafness DFNA1 associated with mutation of a human homolog of the Drosophila gene diaphanous. , 1997, Science.

[33]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[34]  K. Nakao,et al.  p140mDia, a mammalian homolog of Drosophila diaphanous,is a target protein for Rho small GTPase and is a ligand for profilin , 1997, The EMBO journal.

[35]  T. Miyata,et al.  The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. , 1996, The Journal of clinical investigation.

[36]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[37]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[38]  A. Schmidt,et al.  Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. , 1993, The Journal of clinical investigation.

[39]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[40]  U. Engel,et al.  LARG and mDia1 Link Gα12/13 to Cell Polarity and Microtubule Dynamics , 2008 .

[41]  P. Stahl,et al.  Receptor tyrosine kinase signaling and trafficking--paradigms revisited. , 2004, Current topics in microbiology and immunology.

[42]  E. Sahai,et al.  Diaphanous-related formins bridge Rho GTPase and Src tyrosine kinase signaling. , 2000, Molecular cell.

[43]  T. Kislinger,et al.  Blockade of RAGE ± amphoterin signalling suppresses tumour growth and metastases , 2022 .